The multicenter study to examine angiogenesis-related factors in advanced colorectal cancer

Status: Active, no longer recruiting

Phase of Trial: Phase IV

Latest Information Update: 06 Nov 2022

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Aflibercept (Primary) ; Bevacizumab (Primary) ; Ramucirumab (Primary) ; Antineoplastics; Epidermal growth factor receptor antagonists; Fluorouracil; Folinic acid; Irinotecan
Indications Colorectal cancer
Focus Therapeutic Use
Acronyms GI-SCREEN CRC-Ukit

13 Sep 2022 Results (Data from Sep 2017 to Dec 2020,n=295) presented at the 47th European Society for Medical Oncology Congress.
07 Jun 2022 Results investigating whether plasma angiogenesis factors could predict the efficacy of biologics combined with chemo in 1L treatment in patients (pts) with RAS wild-type mCRC, presented at the 58th Annual Meeting of the American Society of Clinical Oncology.
19 Jul 2021 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com